

Colorectal Cancer Endpoints Panel

November 12, 2003

Al B. Benson III, MD

Northwestern University Medical School
Division of Hematology & Oncology
Chicago, IL
Med Onc

Jordan Berlin, MD

Vanderbilt Ingram Cancer Center
Nashville, TN
Med Onc

Charles Blanke, MD

Oregon Health & Science University
Portland, OR
Med Onc

Alfred M. Cohen, MD

Lucille P. Markey Cancer Ctr
Lexington, KY
Surg Onc

Tom Fleming, PhD – statistician

University of Washington
Sch. of Public Health & Community Medicine
Dept of Biostatistics
Seattle, WA

David Kelsen, MD

Memorial Sloan-Kettering Cancer Center
New York, NY
Med Onc

James Krook, MD

Duluth CCOP
Duluth, MN
Med Onc

John Marshall, MD

Lombardi Cancer Center
Washington, DC
Med Onc, Int Med

Langdon Miller, MD – Industry Rep

PTC Therapeutics
South Plainfield, NJ

Meg Mooney, MD

Clinical Investigations Branch
Cancer Therapy and Evaluation Program
National Cancer Institute, NIH

Michael O'Connell, MD (Co-chair)

Allegheny General Hospital
Pittsburgh, PA
Med Onc, Int Med

Nancy Roach – Patient Rep

Marti Nelson Cancer Foundation

Daniel J. Sargent, PhD- statistician, Mayo Clinic & Group Stat for NCCTG, Rochester

Cancer Ctr Statistics
Mayo Clinic
Rochester, MN

Richard L. Schilsky, MD

Biological Sciences Division
University of Chicago
Chicago, IL
Med Onc

FDA Representatives:**Amna Ibrahim, MD**

Medical Officer
Division of Oncology Drug Products, CDER

Patricia Keegan, MD

Division Director
Division of Therapeutic Biological
Oncology Products, CDER

Ning Li, PhD – statistician

Acting Statistical Team Leader
for Division of Oncology Drug Products
Division of Biometrics I
Office of Biostatistics
Office of Pharmacoepidemiology and
Statistical Sciences, CDER

Richard Pazdur, MD (Co-chair)

Division Director
Division of Oncology Drug Products, CDER

Grant Williams, MD

Deputy Director
Division of Oncology Drug Products, CDER